🚀 VC round data is live in beta, check it out!
- Public Comps
- Poly Medicure
Poly Medicure Valuation Multiples
Discover revenue and EBITDA valuation multiples for Poly Medicure and similar public comparables like Conmed, BoneSupport, Kuros Biosciences, Nakanishi and more.
Poly Medicure Overview
About Poly Medicure
Poly Medicure Ltd engages in the manufacturing and sale of medical devices. It offers disposable medical devices for infusion therapy, blood management, gastroenterology, vascular access, surgery and wound drainage, anesthesia, and urology. Some of its products include Ventilator Circuit Combo Kits, Bain Circuits, Safety Introducer Needles, High-Pressure Vaccum Bottle-Triplet, Catheters, and others. Geographically, it derives a majority of its revenue from exports. The company operates under one segment namely Medical Devices.
Founded
1995
HQ

Employees
3.1K
Website
Sectors
Financials (LTM)
EV
$1B
Poly Medicure Financials
Poly Medicure reported last 12-month revenue of $205M and EBITDA of $50M.
In the same LTM period, Poly Medicure generated $140M in gross profit, $50M in EBITDA, and $39M in net income.
Revenue (LTM)
Poly Medicure P&L
In the most recent fiscal year, Poly Medicure reported revenue of $197M and EBITDA of $60M.
Poly Medicure expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $205M | XXX | $197M | XXX | XXX | XXX |
| Gross Profit | $140M | XXX | $103M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $50M | XXX | $60M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $39M | XXX | $40M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | — | — | $18M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Poly Medicure Stock Performance
Poly Medicure has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Poly Medicure's stock price is $13.72.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.4% | XXX | XXX | XXX | $0.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPoly Medicure Valuation Multiples
Poly Medicure trades at 6.3x EV/Revenue multiple, and 26.0x EV/EBITDA.
EV / Revenue (LTM)
Poly Medicure Financial Valuation Multiples
As of March 7, 2026, Poly Medicure has market cap of $1B and EV of $1B.
Equity research analysts estimate Poly Medicure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Poly Medicure has a P/E ratio of 35.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | 26.0x | XXX | 21.8x | XXX | XXX | XXX |
| EV/EBIT | 33.7x | XXX | 28.6x | XXX | XXX | XXX |
| EV/Gross Profit | 9.2x | XXX | 12.5x | XXX | XXX | XXX |
| P/E | 35.8x | XXX | 34.9x | XXX | XXX | XXX |
| EV/FCF | 217.8x | XXX | (131.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Poly Medicure Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Poly Medicure Margins & Growth Rates
Poly Medicure's revenue in the last 12 month grew by 20%.
Poly Medicure's revenue per employee in the last FY averaged $0.1M.
Poly Medicure's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Poly Medicure's rule of X is 75% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Poly Medicure Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | (17%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 75% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Poly Medicure Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Conmed | XXX | XXX | XXX | XXX | XXX | XXX |
| BoneSupport | XXX | XXX | XXX | XXX | XXX | XXX |
| Kuros Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Nakanishi | XXX | XXX | XXX | XXX | XXX | XXX |
| Subgen AI | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Poly Medicure M&A Activity
Poly Medicure acquired XXX companies to date.
Last acquisition by Poly Medicure was on XXXXXXXX, XXXXX. Poly Medicure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Poly Medicure
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPoly Medicure Investment Activity
Poly Medicure invested in XXX companies to date.
Poly Medicure made its latest investment on XXXXXXXX, XXXXX. Poly Medicure invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Poly Medicure
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Poly Medicure
| When was Poly Medicure founded? | Poly Medicure was founded in 1995. |
| Where is Poly Medicure headquartered? | Poly Medicure is headquartered in India. |
| How many employees does Poly Medicure have? | As of today, Poly Medicure has over 3K employees. |
| Is Poly Medicure publicly listed? | Yes, Poly Medicure is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Poly Medicure? | Poly Medicure trades under POLYMED ticker. |
| When did Poly Medicure go public? | Poly Medicure went public in 2011. |
| Who are competitors of Poly Medicure? | Poly Medicure main competitors are Conmed, BoneSupport, Kuros Biosciences, Nakanishi. |
| What is the current market cap of Poly Medicure? | Poly Medicure's current market cap is $1B. |
| What is the current revenue of Poly Medicure? | Poly Medicure's last 12 months revenue is $205M. |
| What is the current revenue growth of Poly Medicure? | Poly Medicure revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Poly Medicure? | Current revenue multiple of Poly Medicure is 6.3x. |
| Is Poly Medicure profitable? | Yes, Poly Medicure is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Poly Medicure? | Poly Medicure's last 12 months EBITDA is $50M. |
| What is Poly Medicure's EBITDA margin? | Poly Medicure's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Poly Medicure? | Current EBITDA multiple of Poly Medicure is 26.0x. |
| What is the current FCF of Poly Medicure? | Poly Medicure's last 12 months FCF is $6M. |
| What is Poly Medicure's FCF margin? | Poly Medicure's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Poly Medicure? | Current FCF multiple of Poly Medicure is 217.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.